Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Untreated prostate cancer can sometimes cause erectile dysfunction (ED). However, ED is more commonly associated with ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

When hormone therapy stops working, the cancer is said to be “castration resistant.” On average, it takes about two years for prostate cancer to become resistant to hormone therapy ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Christian Edouard-Betsy was at work when his doctor called and asked him to meet immediately to discuss the results of a ...

New Data for NUBEQA® Build on Safety and Efficacy Results Across Subgroups of Patients with Metastatic Hormone-Sensitive ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...